Company Description

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China.

The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer’s disease, and dementia.

It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues.

The company is based in Houston, Texas.

Nexalin Technology, Inc.

Country	United States
Founded	2010
IPO Date	Sep 16, 2022
Industry	Medical Devices
Sector	Healthcare
Employees	6
CEO	Mark White

Contact Details

Address: 1776 Yorktown, Suite 550 Houston, Texas 77056 United States
Phone	(832) 260-0222
Website	nexalin.com

Stock Details

Ticker Symbol	NXL
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
IPO Price	$4.15
CIK Code	0001527352
CUSIP Number	65345B201
ISIN Number	US65345B2016
Employer ID	27-5566468
SIC Code	3845

Key Executives

Name	Position
Mark White	President, Chief Executive Officer, Chief Financial Officer and Director
Dr. David Owens M.D.	Chief Medical Officer and Director
Marilyn Elson	Controller
John Patrick Claude	Co-Founder and Director of Engineering and Development
Carolyn Shelton	Senior Vice President of Quality, Regulatory and Clinical Affairs

Latest SEC Filings

Date	Type	Title
Nov 1, 2024	8-K	Current Report
Sep 25, 2024	8-K	Current Report
Sep 19, 2024	8-K	Current Report
Sep 3, 2024	8-K	Current Report
Aug 8, 2024	10-Q	Quarterly Report
Jul 30, 2024	8-K	Current Report
Jul 29, 2024	DEF 14A	Other definitive proxy statements
Jul 16, 2024	8-K	Current Report
Jul 3, 2024	8-K	Current Report
Jul 1, 2024	424B4	Prospectus

View All SEC Filings